First, the study included 103 high-throughput datasets, including 6946 experimental and 5592 control samples, which strongly confirmed the up-regulation of CCNB2 mRNA in CIS and LC through integrated analysis. The gene discussed is CCNB2; the disease is in situ carcinoma.